Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.

Details

Serval ID
serval:BIB_3EA20173538B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
Journal
Journal of Crohn's and Colitis
Author(s)
Schaffer T., Schoepfer A.M., Seibold F.
Working group(s)
Swiss IBD Cohort Study Group
Contributor(s)
Bauerfeind P., Beglinger C., Begré S., Bengoa J., Binek J., Boller D., Borovicka J., Braegger C., Burnand B., Camara R., Criblez D., de Saussure P., Degen L., Delarive J., Ehmann T., Engelmann M., El Wafa A., Felley C., Frei A., Frei R., Fried M., Friedt M., Froehlich F., Gallot-Lavallée S., Gerlach T., Geyer M., Girardin M., Goetze O., Haack H., Hediger S., Hengstler P., Heyland K., Janiak P., Juillerat P., Brondolo VK., Knoblauch C., Kullak-Ublick GA., Manz M., Meier R., Meyenberger C., Michetti P., Mottet C., Müller C., Müllhaupt B., Nicolet T., Nydegger A., Pache I., Piccoli F., Pilz J., Pittet V., Rentsch R., Rey JP., Rihs S., Rogler D., Rogler G., Sagmeister M., Sauter B., Schaub N., Schibli S., Schoepfer AM., Seibold F., Spalinger J., Stadler P., Steuerwald M., Straumann A., Sulz M., Tempia-Caliera M., Thorens£££Joël£££ J. , Vader JP., Vavricka SR., Vögtlin J., Von Känel R., Wachter G., Wermuth J., Wiesel P.
ISSN
1876-4479 (Electronic)
ISSN-L
1873-9946
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
8
Number
9
Pages
1125-1132
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
BACKGROUND AND AIMS: Ficolin-2 is an acute phase reactant produced by the liver and targeted to recognize N-acetyl-glucosamine which is present in bacterial and fungal cell walls. We recently showed that ficolin-2 serum levels were significantly higher in CD patients compared to healthy controls. We aimed to evaluate serum ficolin-2 concentrations in CD patients regarding their correlation with endoscopic severity and to compare them with clinical activity, fecal calprotectin, and CRP.
METHODS: Patients provided fecal and blood samples before undergoing ileo-colonoscopy. Disease activity was scored clinically according to the Harvey-Bradshaw Index (HBI) and endoscopically according to the simplified endoscopic score for CD (SES-CD). Ficolin-2 serum levels and fecal calprotectin levels were measured by ELISA.
RESULTS: A total of 136 CD patients were prospectively included (mean age at inclusion 41.5±15.4 years, 37.5% females). Median HBI was 3 [2-6] points, median SES-CD was 5 [2-8], median fecal calprotectin was 301 [120-703] μg/g, and median serum ficolin-2 was 2.69 [2.02-3.83] μg/mL. SES-CD correlated significantly with calprotectin (R=0.676, P<0.001), CRP (R=0.458, P<0.001), HBI (R=0.385, P<0.001), and serum ficolin-2 levels (R=0.171, P=0.047). Ficolin-2 levels were higher in CD patients with mild endoscopic disease compared to patients in endoscopic remission (P=0.015) but no difference was found between patients with mild, moderate, and severe endoscopic disease.
CONCLUSIONS: Ficolin-2 serum levels correlate worse with endoscopic CD activity when compared to fecal calprotectin or CRP.
Pubmed
Web of science
Open Access
Yes
Create date
23/10/2014 18:54
Last modification date
20/08/2019 13:35
Usage data